The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 56 of the 127 sources its claims cite were checked for support.
Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management
Open accessAbstract
PURPOSE OF REVIEW: Paracetamol (acetaminophen) is among the most widely used medications in the history of humanity for treatment of pain conditions. For more than half a century, it has occupied a unique position as the archetypal first-line analgesic and antipyretic, recommended across age groups, clinical settings, and healthcare systems. Its remarkable success has been based on three fundamental assumptions: it is effective for common painful conditions, substantially safer than alternative analgesics, and suitable for broad population use with minimal restrictions. Over the last two decades, however, these assumptions have been increasingly challenged by accumulating evidence from randomized trials, systematic reviews, pharmaco-epidemiological studies, and regulatory analyses. RECENT FINDINGS: The history of paracetamol represents an instructive example of evidence reversal in modern medicine and pain management. Originally introduced as a safer successor to phenacetin, paracetamol benefited from a favorable safety reputation that often exceeded the available scientific evidence. Subsequent investigations have revealed a more complex reality. Hepatotoxicity has emerged as a leading cause of acute liver failure worldwide, efficacy in chronic musculoskeletal disorders has proved substantially lower than previously assumed, and concerns regarding long-term safety and use during pregnancy have generated ongoing scientific debate. Simultaneously, clinical practice and prescribing habits remained largely unchanged despite evolving evidence and repeated modifications of international guidelines. By examining major assumptions, scientific misconceptions, regulatory decisions, and evidence reversals, this review explores how one of medicine's most familiar drugs in pain medicine became a paradigm of the challenges inherent in translating evolving scientific evidence into clinical practice. Beyond paracetamol itself, this story provides broader lessons regarding therapeutic inertia, medical dogma, risk perception, and the dynamic nature of evidence-based medicine.
Overview
CoChat Summary
TL;DR
This narrative review uses paracetamol as a case study of evidence reversal: long-standing assumptions of broad efficacy, safety, and universal use were challenged by later trials, meta-analyses, safety signals, and guideline changes. It argues that clinical use persisted despite this reassessment, illustrating therapeutic inertia and the evidence-practice gap.
Key findings
- The review identifies three foundational assumptions that drove paracetamol’s adoption—effective analgesia for common pain, safety relative to alternatives, and broad use across populations—and says each was substantially reassessed over the last two decades.
- Efficacy in chronic pain was challenged: the PACE trial found paracetamol no more effective than placebo for acute low back pain across pain intensity, disability, recovery time, sleep quality, and quality of life; Machado et al. found no meaningful benefit for spinal pain and only minimal, clinically insignificant osteoarthritis improvement, with a pooled low back pain effect of approximately −0.5 on a 0–100 pain scale.
- Safety concerns expanded beyond hepatotoxicity: Roberts et al. reported consistent dose-response relationships across several adverse outcomes, and the review notes possible cardiovascular, hypertension, gastrointestinal, renal, and mortality risks at the upper therapeutic range; the FDA restricted paracetamol in prescription combination products to 325 mg per dosage unit.
- Guideline and regulatory reversals occurred alongside persistent use: the ACR/Arthritis Foundation downgraded paracetamol to a conditional recommendation in 2019, while real-world studies show it remains a commonly prescribed first-line analgesic for low back pain and osteoarthritis; for pregnancy/neurodevelopment, a sibling-control analysis in nearly 2.5 million children attenuated associations toward the null, and a 2025 umbrella review concluded existing evidence does not clearly establish a link with autism or ADHD.
Methods
- Structured historical narrative review conducted and reported according to SANRA principles, intended as a broad historical and interpretative synthesis rather than a systematic review or meta-analysis.
- Literature searched in PubMed/MEDLINE, Scopus, Web of Science, and Embase from database inception through June 1, 2026, with manual reference-list checks; two reviewers independently screened sources, with a third senior reviewer resolving disagreements.
- Qualitative thematic synthesis organized around chronological-conceptual phases (discovery, successor status, “safe analgesic” paradigm, mechanisms, efficacy reassessment, safety concerns, regulatory responses, persistence of use); no formal risk-of-bias assessment was performed.
Limitations
- The paper states that, as a narrative review, source selection and interpretation involve author judgment; conclusions are an evidence-informed historical analysis, not quantitative treatment-effect estimates.
- The paper states that long-term safety evidence is largely observational and vulnerable to confounding by indication, channeling bias, and residual confounding, so associations cannot be equated with causation; efficacy trials differ in dose, duration, comparator, and population and mainly address chronic musculoskeletal conditions.
- The paper states that pregnancy/neurodevelopment evidence is rapidly evolving and contested, so the balance of evidence may shift; evident from the text, no formal risk-of-bias assessment or quantitative pooling was performed, and no datasets were generated or analyzed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Evolution of the proposed mechanism of action of paracetamol. Early models attributed its analgesic and antipyretic effects to central inhibition of prostaglandin synthesis and a putative COX-3 isoform proposed in 2002, a single-target hypothesis subsequently unsupported in humans [26]. Contemporary models describe a multimodal central network: after systemic/hepatic metabolism to p-aminophenol](https://figures.cochat.ai/paper-figures/bc2fb7a0243b4435952b5799cced4a3a/paracetamol-a-history-of-assumptions-errors-and-evidence-reversals-in-pain-figure-2.png)
Verification
Claims the paper makes
39 Valid · 1 Not valid · 39 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In many healthcare systems, paracetamol became the default analgesic against which alternative therapies were compared [ 32 ].”
What the sources say
- Partly supportedcites [32] Petrides M, Peletidi A, Petrou C, Nena E, Papavasili M, Constantinidis T, et al. Exploring public knowledge and perceptions regarding per os OTC pain-relieving medications: the case of paracetamol (acetaminophen). J Pharm Policy Pract. 2023;16(1):93. sourceExperimental — accuracy not yet measured
The Background (page not available in our copy) describes paracetamol as one of the most frequently used analgesics internationally, supporting its widespread use. It does not say that healthcare systems adopted it as a default analgesic or that alternative therapies were compared against it. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Paracetamol continues to occupy a privileged position within healthcare systems despite growing uncertainty regarding its efficacy in many chronic pain conditions [ 2 , 9 , 18 ].”
What the sources say
- Supportedcites [2] Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E, Paracetamol. A Review of Guideline Recommendations. J Clin Med. 2021;10(15):3420. source
The Introduction says paracetamol remains a recommended analgesic despite reports that its efficacy may be lower than previously thought. Section 5.2 (Chronic Pain) says evidence of reduced efficacy has changed some guidelines, yet paracetamol continues to be used and recommended by several others. Section 7 also reports uncertainty about its efficacy in common pain conditions. (LLM, conf=0.91)
- Partly supportedcites [9] Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225. sourceExperimental — accuracy not yet measured
The Introduction says guidelines consistently recommend paracetamol as a first-line analgesic for spinal pain and hip or knee osteoarthritis, supporting its privileged position in care. The ‘What This Study Adds’ section questions its efficacy for low back pain and finds only a small, clinically unimportant benefit for hip or knee osteoarthritis. The claim’s reference to ‘many chronic pain conditions’ reaches beyond the conditions this review assesses; the paper says its effects for neck pain are unknown. (LLM, conf=0.83)
- Partly supportedcites [18] Pickering G, Mezouar L, Kechemir H, Ebel-Bitoun C. Paracetamol Use in Patients with Osteoarthritis and Lower Back Pain: Infodemiology Study and Observational Analysis of Electronic Medical Record Data. JMIR Public Health Surveill. 2022;8(10):e37790. sourceExperimental — accuracy not yet measured
The Introduction describes paracetamol as a commonly used first-line analgesic for osteoarthritis and lower back pain, while the Discussion reports conflicting efficacy evidence and continued prescribing despite divergent guidelines. The paper supports the claim for those conditions, but does not establish a privileged position across healthcare systems or uncertainty about efficacy in many chronic pain conditions more broadly. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Contemporary reviews have consistently concluded that paracetamol offers limited or negligible efficacy in chronic low back pain”
What the sources say
- Supportedcites [10] Jones CMP, Underwood M, Chou R, Schoene M, Sabzwari S, Cavanagh J, et al. Analgesia for non-specific low back pain. BMJ. 2024;385:e080064. source
The Paracetamol subsection states that moderate- to high-certainty evidence shows no effect over placebo for both acute and chronic low back pain. The efficacy table reports essentially no pain benefit in the systematic review it summarizes. No page numbers are provided in our copy. (LLM, conf=0.91)
- Partly supportedcites [39] Leopoldino AO, Machado GC, Ferreira PH, Pinheiro MB, Day R, McLachlan AJ, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2(2):CD013273. sourceExperimental — accuracy not yet measured
The Authors’ conclusions (page not available) find only minimal improvements from paracetamol, but specifically for hip or knee osteoarthritis. The review does not establish limited efficacy in chronic low back pain or that reviews have consistently reached that conclusion for that condition; its Additional information section mentions a low-back-pain trial only in a disclosure. (LLM, conf=0.83)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A landmark systematic review by Roberts et al. [ 15 ] demonstrated consistent dose-response relationships across several adverse outcomes”
What the sources say
- Supportedcites [15] Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552–9. source
The Discussion states that the review found a consistent dose–response relationship between paracetamol use and several adverse outcomes, including mortality, cardiovascular, gastrointestinal and renal events. The paper notes that the evidence came from observational studies and was rated low or very low quality. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Quantitatively, the pooled effect on low back pain was indistinguishable from placebo (weighted mean difference of approximately − 0.5 on a 0-100 pain scale)”
What the sources say
- Partly supportedcites [9] Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225. sourceExperimental — accuracy not yet measured
The Short term follow-up section reports a weighted mean difference of −0.5 and no effect on low back pain, but that estimate comes from one trial, not a pooled analysis. The pooled immediate-term estimate in the spinal pain section is 1.4 (95% CI −1.3 to 4.1), also showing no effect. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 16 with their cited sources checked
Create a free account to see all 115 claims and every source verdict.
- It may state two separate claims as one. 49
- Probably not a substantial claim. 20
- Not yet classified. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Conflict of Interest Dr. Kaye discloses his role as editor-in-chief of the Current Pain and Headache Reports Journal.”
“Competing Interests The authors declare no competing interests.”
Citations
Cites
SANRA—a scale for the quality assessment of narrative review articles
Baethge, C., Goldbeck-Wood, S., & Mertens, S. (2019) · Research Integrity and Peer Review · doi:10.1186/s41073-019-0064-8 · Cited by 3,469
The answer is 17 years, what is the question: understanding time lags in translational research
Morris, Z. S., Wooding, S., & Grant, J. (2011) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2011.110180 · Cited by 3,340
Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Jordan, K. M., Arden, N. K., Doherty, M., Bannwarth, B., Bijlsma, J. W. J., Dieppe, P., Gunther, K., Hauselmann, H., Herrero-Beaumont, G., Kaklamanis, P., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011742 · Cited by 2,048
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Phillips, L. S., Branch, W. T., Cook, C. B., Doyle, J. P., El-Kebbi, I. M., Gallina, D. L., Miller, C. D., Ziemer, D. C., & Barnes, C. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-9-200111060-00012 · Cited by 1,370
Cognitive biases associated with medical decisions: a systematic review
Saposnik, G., Redelmeier, D., Ruff, C. C., & Tobler, P. N. (2016) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-016-0377-1 · Cited by 1,001
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Machado, G. C., Maher, C. G., Ferreira, P. H., Pinheiro, M. B., Lin, C.-W. C., Day, R. O., McLachlan, A. J., & Ferreira, M. L. (2015) · BMJ · doi:10.1136/bmj.h1225 · Cited by 580
Research works printed but not linked: 8
- National Guideline C. Evidence review for pharmacological management of sciatica: Low back pain and sciatica in over 16s: assessment and management: Evidence review A. London: National Institute for Health and Care Excellence (NICE); 2020.
- Schaffer DH, Murray BP, Khazaeni B. Acetaminophen Toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.
- Morse HN, Remsen I, Iles MW. On the Oxidation of Bromethyl-toluene and of Similar Substitution-products. Baltimore, MD: Johns Hopkins University; 1878.
- Food, Drug A. Acetaminophen Over-the-Counter (OTC) Monograph and Historical Review Board Proceedings (1950–2010). Pre-2011 Regulatory Framework Review. Silver Spring, MD: US Food and Drug Administration; 2010.
- Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action. Temp (Austin). 2021;8(4):351–71.
- Tittarelli R, Pellegrini M, Scarpellini MG, Marinelli E, Bruti V, di Luca NM, et al. Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):95–101.
- National Collaborating Centre for Primary C. Low Back Pain: Early Management of Persistent Non-specific Low Back Pain. London: Royal College of General Practitioners (UK); 2009.
- Ben Saad H, Barki C, Dergaa I, Dhahbi W, Ceylan Hİ, Chalghaf N, et al. Paracetamol in pregnancy: navigating clinical uncertainty and avoiding the communication pitfalls of the measles, mumps, and rubella–autism controversy: a narrative review. EXCLI J. 2026;25:400–26.
Metadata
- Authors
- Nicolas, J., Leoni, M. L. G., Van Tran, Y., Van Phong, P., Farì, G., Puttini, P. S., Kaye, A. D., & Varrassi, G.
- Affiliations
- Hôpital Paris Saint-Joseph (FR)
- Fondazione Paolo Procacci (IT)
- University of Salento (IT)
- Louisiana State University Health Sciences Center Shreveport (US)
- University of Baghdad (IQ)
- Corresponding author
- Kaye, Alan D.
- Venue
- Current Pain and Headache Reports
- Published
- 2026-09-12
- Volume
- 30
- Issue
- 1
- ISSN
- 1531-3433 (ISSN-L)
- 1534-3081
- PMC
- PMC13570823
- OpenAlex
- W7212372627
- Cited by
- 0
- References
- 57
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Pain and Headache Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- paracetamol, analgesic safety, hepatotoxicity, acute liver failure, chronic musculoskeletal pain, therapeutic inertia, medical dogma, risk perception, evidence-based medicine, drug regulation, prescribing patterns, phenacetin
- MeSH terms
- Acetaminophen, Humans, Pain, Analgesics, Non-Narcotic, Evidence-Based Medicine, History, 20th Century, History, 21st Century, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management. https://app.cochat.ai/papers/10.1007/s11916-026-01553-w
- The paper
- Nicolas, J., Leoni, M. L. G., Van Tran, Y., Van Phong, P., Farì, G., Puttini, P. S., Kaye, A. D., & Varrassi, G. (2026). Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management. Current Pain and Headache Reports. https://doi.org/10.1007/s11916-026-01553-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.